These authors contributed equally to this study.
1872-034X/asset/olbannerleft.gif?v=1&s=1d5d20ad4f644eef0b3d8deb815ca6105d505580)
1872-034X/asset/olbannercenter.gif?v=1&s=39c0f904e07466028315143a0df9c91855a95442)
1872-034X/asset/olbannerright.gif?v=1&s=c9b495ce97cb4ab29a66545dafab38d55e57d7c5)
Original Article
Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B
Article first published online: 26 JUL 2012
DOI: 10.1111/j.1872-034X.2012.01065.x
© 2012 The Japan Society of Hepatology
Additional Information
How to Cite
Kim, S. S., Lee, D., Lee, M. H., Cheong, J. Y. and Cho, S. W. (2013), Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatology Research, 43: 219–227. doi: 10.1111/j.1872-034X.2012.01065.x
- †
These authors contributed equally to this study.
Publication History
- Issue published online: 26 FEB 2013
- Article first published online: 26 JUL 2012
- Accepted manuscript online: 27 JUN 2012 05:04AM EST
- Received 17 May 2012; revision 12 June 2012; accepted 19 June 2012.
- Abstract
- Article
- References
- Cited By
Keywords:
- chronic hepatitis B;
- hepatitis B e-antigen seroconversion;
- hepatitis B surface antigen;
- nucleos(t)ide analog;
- virological response
Aim: This study evaluated the on-treatment serum hepatitis B surface antigen (HBsAg) level during nucleos(t)ide analog (NUC) therapy and the correlation with off-treatment sustained virological response (SVR).
Methods: Fifty-one consecutive patients with hepatitis B e-antigen (HBeAg) positive chronic hepatitis B who achieved HBeAg loss/seroconversion after NUC therapy and completed 12 months or more of additional therapy were included. Serum HBsAg and hepatitis B virus (HBV) DNA levels were determined at baseline, 3, 6, 9 and 12 months, and at the end of treatment. SVR was defined as HBV DNA levels of less than 10 000 copies/mL until 6 or 12 months off-treatment without reappearance of HBeAg.
Results: Twenty-two (43.1%) and 13 (25.5%) patients maintained SVR at 6 and 12 months off-treatment, respectively. In univariate analyses, a decline of HBsAg of 0.5 log10 IU/mL or less at 6 months (P = 0.006) and 12 months (P = 0.013), the mean change in HBsAg level at 6 months (P = 0.024), and lamivudine or entecavir treatment (P = 0.019) were significant predictive factors for SVR at 6 months off-treatment. A decline of HBsAg of 0.5 log10 IU/mL or less at 6 months and lamivudine or entecavir treatment were independent factors on multivariate analyses (odds ratio [OR], 16.67; 95% confidence interval [CI], 1.86–142.86 [P = 0.012]; and OR, 14.83; 95% CI, 1.18–185.73 [P = 0.036]; respectively).
Conclusion: On-treatment serum HBsAg level predicted early off-treatment SVR to NUC therapy in patients infected with genotype C.